FS222 First in Human Study in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in adult participants diagnosed with advanced tumours to
characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is
a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to
systematically assess safety and tolerability, and to identify the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours.
Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.